Maria Kuksin

Ms. Maria Kuksin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in European Journal of Cancer
Verified
Journal Article
Open access
MKMaria Kuksin
Maria Kuksin
DMDaphné Morel
Daphné Morel
MAMarine Aglave
Marine Aglave
FDFrançois-Xavier Danlos
François-Xavier Danlos
AMAurélien Marabelle
Aurélien Marabelle
LVLoïc Verlingue
Loïc Verlingue
The rising interest for precise characterization of the tumour immune contexture has recently brought forward the high potential of RNA sequencing (RNA-seq) in identifying molecular mechanisms engaged in the response to immunotherapy. In this review, we provide an overview of the major principles of single-cell and conventional (bulk) RNA-seq applied to onco-immunology. We describe standard preprocessing and statistical analyses of data obtained from such techniques and highlight some computational challenges relative to the sequencing of individual cells. We notably provide examples of gene expression analyses such as differential expression analysis, dimensionality reduction, clustering and enrichment analysis. Additionally, we used public data sets to exemplify how deconvolution algorithms can identify and quantify multiple immune subpopulations from either bulk or single-cell RNA-seq. We give examples of machine and deep learning models used to predict patient outcomes and treatment effect from high-dimensional data. Finally, we balance the strengths and weaknesses of single-cell and bulk RNA-seq regarding their applications in the clinic.

20 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
LMLeire de Campos Mata
Leire de Campos Mata
JPjanet pinero
janet pinero
SVSonia Tejedor Vaquero
Sonia Tejedor Vaquero
RTRoser Tachó-Piñot
Roser Tachó-Piñot
MKMaria Kuksin
Maria Kuksin
GMGiuliana Magri
Giuliana Magri
Summary: The production of SARS-CoV-2-specific neutralizing antibodies is widely considered as a key mechanism for COVID-19 resolution and protection. However, beyond their protective function, antibodies to SARS-CoV-2 may also participate in disease pathogenesis. To explore the potential relationship between virus-specific humoral responses and COVID-19 immunopathology, we measured serum antibody classes and subclasses to the receptor-binding domain of the SARS-CoV-2 spike protein and the nucleoprotein in a cohort of hospitalized COVID-19 patients with moderate to severe disease. We found that RBD-specific IgG1 and IgG3 dominated the humoral response to SARS-CoV-2, were more abundant in severe patients, and positively correlated with several clinical parameters of inflammation. In contrast, a virus-specific IgA2 response skewed toward RBD rather than NP associated with a more favorable clinical course. Interestingly, RBD-dominant IgA2 responses were mostly detected in patients with gastrointestinal symptoms, suggesting the possible involvement of intrinsically tolerogenic gut immune pathways in the attenuation of virus-induced inflammation and disease resolution.

5 June 2026 in European Journal of Cancer
Verified
Journal Article
Open access
MKMaria Kuksin
Maria Kuksin
SMSeverine Mouraud
Severine Mouraud
DBDelphine Bredel
Delphine Bredel
CRCamelia Radulescu
Camelia Radulescu
CMChifaou Mohamed-Djalim
Chifaou Mohamed-Djalim
AMAurélien Marabelle
Aurélien Marabelle
In the tumor microenvironment, immune, stromal and cancer cells interact. They communicate in paracrine and autocrine manners via secreted cytokines, altering anti-tumor immunity. The pattern consisting of the relative secretions of these proteins is referred-to as the "immune secretome". To date, the immune secretome of human cancers remains largely unexplored. Herein, we describe the dominant cytokines released by human tumors. We analyzed multiple prospectively collected samples of tumoral and peritumoral tissues. After surgical resection, we promptly titered 40 cytokines released by the samples. Macrophage migration Inhibitory Factor (MIF), Chemokine (C-C motif) ligand 21 (CCL21) and Interleukin 16 (IL-16) were the most strongly detected cytokines in the human tumor secretome. Surprisingly, GM-CSF, IL-10 and IL-2 were undetectable or measured at low levels. Moreover, we observed significant differences in cytokine secretions across different tumor histotypes: while liver metastases, head and neck carcinomas and thyroid tumors secreted large amounts of cytokines (103-105 pg/ gram of tissue across most analytes), the other histotypes secreted at least 10-100 times less of each cytokine per gram of tissue. The liver metastases secreted particularly high amounts of CCL21, IL-16, CXCL10, CCL24 and CCL15, but had low CD45 + cell infiltrates compared to primary tumors. We also found that tumor tissues secreted significantly higher quantities of CXCL1 and CXCL9 than surrounding healthy tissues. Tumor histology is not associated with a specific secretome, but subgroups of patients share similar secretome profiles independently from their cancer type. This finding supports the development of biology-oriented tumor-agnostic immunotherapy strategies. As the secretome interacts with tumor-infiltrating T-cells, the cytokines identified within it become potential therapeutic targets for personalized cancer immunotherapy.

16 October 2024 in Children
Verified
Journal Article
Open access
PDF file
MKMaria Kuksin
Maria Kuksin
VJValeska BIDAULT JOURDAINNE
Valeska BIDAULT JOURDAINNE
GRGuillaume Rossignol
Guillaume Rossignol
PAPhilippe AEGERTER
Philippe AEGERTER
GHGéraldine Hery
Géraldine Hery
Florent GuérinFlorent Guérin
Florent Guérin
Background/Objectives: In paediatric liver transplantation, donor–recipient compatibility depends on graft size. We explored whether the graft weight can be predicted using the donor’s biometric parameters. Methods: We used seven easily available biometric variables in 142 anonymised paediatric and adult donors, with data collected between 2016 and 2022. The whole or partial liver was transplanted in our hospital from these donors. We identified the variables that had the strongest correlation to our response variable: whole liver graft weight. Results: In child donors, we determined two linear models: using donor weight and height on the one hand and using donor weight and right liver span on the other hand. Both models had a coefficient of determination R2 = 0.86 and p-value < 10−5. We also determined two models in adult donors using donor weight and height (R2 = 0.33, p < 10−4) and donor weight and sternal height (R2 = 0.38, p < 10−4). The models proved valid based on our external dataset of 245 patients from two institutions. Conclusions: In clinical practise, our models could provide rapidly accessible estimates to determine whole graft dimension compatibility in liver transplantation in children and adults. Determining similar models predicting the left lobe and lateral segment weight could prove invaluable in paediatric transplantation.

22 December 2021 in Novosti Khirurgii
Verified
Journal Article
Closed access
SUS.P. Grigoriev Institute of Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine
S.P. Grigoriev Institute of Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine
YRYev.B. Radzishevska
Yev.B. Radzishevska
KUKharkiv National Medical University
Kharkiv National Medical University
ASA.S. Savchenko
A.S. Savchenko
KVKharkiv State University named after V.N.Karazin
Kharkiv State University named after V.N.Karazin
ÉSÉcole Normale Supérieure
École Normale Supérieure
Objective. Evaluate the potential long-term effects of differentiated thyroid cancer (DTC) treatment, on the gastro-intestinal tract (GIT) based on a retrospective study of DTC patients. Methods. Occurrence of long-term GIT pathologies was retrospectively studied in 157 DTC patients. All patients were treated according to the standard of care, which includes radical surgery, radiation therapy and hormone therapy. The database contained digitalised medical histories of patients followed for at least 1 year after treatment. A total of 463 entries were available, representing one entry per noted consequence for each of the 157 patients. The study focused on two aspects. The frequencies of complications before and after treatment were compared, and factors impacting DTC pathology in a statistically significant manner were isolated. Results: The total onset frequency of gallbladder, liver and pancreas disorders was increased by a factor of 1.6 in a statistically significant manner in DTC patients. Patients initially presenting gallbladder disorders received shorter cures of hormone therapy (4 versus 13 months), and lower levels of L-thyroxine in a context of uncompensated hypothyroidism (2.3 versus 3.5 mg/kg). A statistically significant relation was established between the total duration of breastfeeding in women presenting metabolic health disorders, and onset of liver pathology (essentially non-alcoholic steatohepatitis). Conclusion. Life-long GIT pathology monitoring should be standard of care for patients after special DTC treatment. What this paper adds The long-term effects of treatment of differentiated thyroid cancer on the gastro-intestinal tract have never been described to date. Here, a 1.6-fold increase in disorders implicating mainly the gallbladder, liver and pancreas is noted. Gallbladder disorders are shown to be frequent in patients undergoing short courses of thyroid hormone suppression therapy with low levels of L-thyroxine and presenting uncompensated hypothyroidism. In women presenting metabolic disorders, a relation has been established between the total duration of breastfeeding and the later development of liver pathologies.